BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the most promising biotech stocks to buy according to hedge funds. In the second quarter, Tealwood Asset Management Inc. expanded its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 37.4%. After the purchase of 5,874 shares, the fund now owns 21,563 shares of the company’s stock, translating to an investment worth $1,185,000. Three words best describe the future of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): valuation, growth, and pipeline. Wit ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the most promising biotech stocks to buy according to hedge funds. During the second quarter, Wealth Enhancement Advisory Services LLC trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 64.5% through the offloading of 9,286 shares. According to the latest filing with the SEC, the institutional investor now owns 5,118 shares of the company’s stock, worth $1,699,000. It’s truly exciting to see the company’s robust clinical productivity ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the most promising biotech stocks to buy according to hedge funds. Analysts at Piper Sandler have reaffirmed their ‘Overweight’ rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) with an unchanged price target of $68, implying an upside potential of nearly 33%. This confidence is driven by the company’s unique efficacy profile that strengthens its launch dynamics. During the conversation with the research firm’s team, management revealed that third-quarter perform ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds. According to a recent disclosure with the SEC, Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by a whopping 439.0% during the second quarter. Following the acquisition of 947,865 shares, the firm now owns 1,163,755 shares of the company’s stock, reflecting an investment worth $42,314,000 and ownership of about 1.23%. During the latest ...

Revolution Medicines, Inc. (NASDAQ:RVMD) is among the most promising biotech stocks to buy according to hedge funds. On September 24, 2025, General Counsel and Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), Jeff Cislini, offloaded 1,799 shares of common stock, priced at $44.26 per share. This transaction of $79,623 leaves the ownership of Cislini to 50,425 shares of the company’s stock, including 43,910 restricted stock units. Just recently, Revolution Medicines, Inc. (NASDAQ:RVMD) reported outstand ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most promising biotech stocks to buy according to hedge funds. During the second quarter, Generate Investment Management Ltd acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) through the purchase of 12,000 shares of the company’s stock. According to a recent disclosure with the SEC, the firm’s investment in the company is approximately $6,300,000 now. While the company’s returns don’t seem quite compelling, Regeneron Pharmaceut ...

Insmed Incorporated (NASDAQ:INSM) is among the most promising biotech stocks to buy according to hedge funds. In the second quarter, Public Employees Retirement System of Ohio acquired a new stake in Insmed Incorporated (NASDAQ:INSM) through the purchase of 55,425 shares. According to a recent disclosure with the SEC, the fund’s investment in the company amounts to approximately $5,578,000. During the presentation at the Morgan Stanley 23rd Annual Global Healthcare Conference, management revealed that Ins ...

Lanson-BCC has had its €50m ($58m) offer for the purchase of Champagne house Heidsieck & Co. Monopole accepted by Vranken-Pommery Monopole. Last month, Vranken-Pommery said it was in "exclusive negotiations" to buy Heidsieck & Co. Earlier in September the group had said it had begun the the process to offload the Champagne house to majority shareholder Compagnie Vranken. In a statement yesterday (1 October), Vranken-Pommery said the acquisition will take effect from January next year. Heidsieck & Co Mo ...

Key Points Roblox stock has more than tripled in a year, thanks to strong business results. Management still has a massive growth opportunity ahead of it. If the company can achieve its goals, the current valuation could seem extremely cheap. 10 stocks we like better than Roblox › Roblox (NYSE: RBLX) shares have more than tripled over the past year, but the stock isn't getting nearly as much attention as several others with similar returns. While many investors avoid Roblox because of certain cont ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Barclays upgraded Charles River (CRL) to Overweight from Equal Weight with a price target of $195, up from $165. The firm cites stabilized drug discovery demand and valuation for the upgrade.Barclays upgraded C.H. Robinson (CHRW) to Equal Weight from Underweight with a price target of $130, up from $95. The upgrad ...